Sorrento Therapeutics (SRNE) rises 10% on COVID-19 (SARS-CoV-2) coronavirus vaccine candidate

Sorrento Therapeutics (SRNE) has tremendously risen 10% as the company announces a COVID-19 (SARS-CoV-2) coronavirus vaccine candidate.

T-VIVA-19 is a recombinant protein fusion of the S1-domain spike protein and the Fc part of the human IgG1 antibody (rS1-Fc). The rS1-Fc had either been inserted into a mouse’s vein or thigh muscle. Three weeks later (on the same route as the initial injection) the mice were given a booster shot, and immune responses to SARS-CoV-2 were tested.

Within the first week of administration, immunization with the rS1-Fc protein via intramuscular and intravenous injections induced antibodies to the SARS-CoV-2 protein in all mice. Antibodies have been observed to be enhanced when a booster is given. Around 80 per cent of the sera mice had antibodies that were neutralizing and completely prevented virus infection in in vitro cell cultures using 100 TCID50 viruses and VERO cells.

If successful and approved, we plan to produce the T-VIVA-19 vaccine in our therapeutic antibody cGMP production facility in San Diego. Due to the potentially low dose administration of T-VIVA-19, which may be one milligram per person or less, we believe our existing cGMP manufacturing facility is capable of producing bulk drug substance rS1-Fc for up to 100 million doses a month. Unlike other vaccine candidates, our rS1-Fc protein production could utilize our existing therapeutic antibody manufacturing processes, and we therefore believe it would be simple and easy to scale up.

Dr. Henry Ji, Chairman & CEO of Sorrento Therapeutics (SRNE)

The company plans to take this through the clinical and regulatory process which will include the Food & Drug Administration (FDA)’s stance on the matter. Shortly after, mass scale and commercial distribution will occur.

Conclusion: is Sorrento Therapeutics (SRNE) a worthy investment for COVID-19 (SARS-CoV-2) coronavirus?

Shares of Sorrento Therapeutics (SRNE) appear to be a very good investment option, with Wall Street analysts expecting its price to rise considerably in the next several months. The majority of the metrics point to this investment being highly attractive.

Looking for an easier way to beat the market? Get Money Signals straight to your phone with over 50% in profits! Join now!

Tim Rolle
Tim Rolle

Investor of 6 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.

Articles: 117

Newsletter Updates

Enter your email address below to subscribe to our newsletter